Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma

Eur J Cancer Clin Oncol. 1986 Jul;22(7):879-81. doi: 10.1016/0277-5379(86)90377-9.

Abstract

Twenty-seven patients with disseminated malignant melanoma were treated with combination chemotherapy consisting of bleomycin, actinomycin D, DTIC and vindesine. There were 4 complete responses in patients with pulmonary metastasis, 5 patients had a partial remission, 2 of them had mainly lung lesions. Toxicity consisted mainly of leuco- and thrombocytopenia of short duration and sporadic severe mucositis.

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage
  • Dacarbazine / administration & dosage
  • Dactinomycin / administration & dosage
  • Drug Evaluation
  • Female
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary
  • Male
  • Melanoma / drug therapy*
  • Middle Aged
  • Vindesine / administration & dosage

Substances

  • Bleomycin
  • Dactinomycin
  • Dacarbazine
  • Vindesine